Toray Industries has acquired a stake in a Japanese CMO and ingredient supplier as part of its push into life sciences.
UK-based biotech ValiRx has acquired a biomarkers business from Finnish preclinical CRO Pharmatest Services.
Charles River wants to buy drug discovery assets to meet interest in strategic outsourcing of non-regulated efficacy testing.
Schulman Associates buys Florida IRB
Cincinnati, US-based Schulman Associates Institutional Review Board (IRB) has bought Florida counterpart Independent Investigational Review Board (IIR) to broaden its offering for Pharmas and CROs.
UBC looking to ‘buy or build’ to serve strategic partnerships
UBC expects strategic outsourcing of outcomes and personalised medicine research to accelerate as biopharm cut fixed costs.
Forming CRO spin-outs can help big pharma; research
Spinning-out assets to form a CRO can help large biopharm commercialise knowledge and focus on core activities, research found.
SeraCare posts Q4 loss after bioservice revenue halves
SeraCare slipped into the red in the fourth quarter as loss of government business halved bioservice revenues.
UCB inks deal with Parexel & PRA to boost cost-effectiveness
UCB has inked a strategic deal with Parexel and PRA that an analyst believes has “very favourable” terms for the biopharm.
Patheon is considering buying unique drug delivery technologies to expand its development service capabilities.
PDI operating profit falls as DCA buy drags on performance
Operating profit at PDI fell 90 per cent in the third quarter after the acquired digital communications unit again dragged on performance.
Catalent is considering acquisitions as it adds scale, drug delivery technologies and capacity in emerging markets.
Effective outsourcers will have competitive edge in 2020; KPMG
Effectively outsourcing a significant portion of work will give biopharm a competitive advantage in 2020, KPMG said.
Quintiles makes acquisitions in observational research and market access space
Quintiles has bought its way into the observational research space with the acquisition of Outcome Sciences and strengthened its market access standing with the purchase of VCG & Associates.
JSS & Venn partner to offer transatlantic clinical services
JSS Medical Research has bought Canadian assets from Venn Life Sciences as part of a joint-venture spanning North America and Europe.
Encorium seeks partner or PE buyer after loss of biz
Encorium is seeking a CRO partner or private equity buyer after the strategic outsourcing trend hit its revenues and cash reserves.
Akorn to enter India in five facility takeover deal
Akorn is to expand its CMO business into India and add sterile injectables capabilities by acquiring five manufacturing plants.
AmerisourceBergen to buy reimbursement services firm TheraCom for $250m
AmerisourceBergen will buy patient access and reimbursement support services firm TheraCom, continuing its recent run of acquisitions.
PPD accepts $3.9bn offer
PPD has agreed to be acquired by two private equity firms for $3.9bn (€3.0bn) in cash.
CEO hire signals private equity unlikely to buy PPD; analyst
PPD has named a new CEO and is now unlikely to be taken over by private equity because the deal environment has worsened, an equity analyst said.
Patheon plans facility exits & capability cuts to improve biz
Patheon is exiting semi-solids, clinical packaging and cutting facilities in response to ‘poor historical performance’.
inVentiv plans Asian expansion
inVentiv Health is looking to expand operations in Japan, China and India after completing takeovers of i3 and PharmaNet.
Over 50% of sales at top CROs now made outside US; report
Big public CROs now generate more than half their collective revenue outside the US after triple-digit growth in recent years, a report found.
Strategic deals drive Catalent’s $410m move for Aptuit assets
Catalent is to buy clinical trial supply assets from Aptuit for $410m (€285m) as it adds scale to handle the shift to preferred provider relationships.
Akela plans CMO buys after exiting development project
Akela Pharma is focusing on its CMO and expanding it through acquisitions after its partner exited their drug development programme.
ICIG takes Roche Colorado in bid to flex contract peptide manufacturing muscle
International Chemical Investors Group (ICIG) will take over Roche’s Colorado API plant in a bid to gain footing in the peptide manufacturing industry.
DSM seeks CMO partner to diversify beyond big pharma
DSM wants to form a CMO joint venture to become less reliant on big pharma clients and revive the flagging business unit.
CRO integration post-M&A will be very difficult; Covance
The CEO of Covance has warned it will be “very, very difficult” for CROs expanding through M&A to integrate assets, and the process could see clients go elsewhere.
AmerisourceBergen eyes M&A as takeover war chest grows
AmerisourceBergen is looking to buy pharmaceutical packaging and distribution assets using some of the $2bn (€1.4bn) it has accumulated.
INC Research CEO James Ogle tells Outsourcing-pharma.com that the acquisition of fellow CRO Kendle was about building a presence in emerging trial hotspots and pharmaceutical markets.
Alkermes - EDT merger to spark consolidation & strategic shift
EDT will accelerate its shift to proprietary products and consolidate to save $20m when its takeover by Alkermes closes.
PPD reportedly considering a sale as results season nears
CRO financial results season begins this week amid reports PPD could be sold, with other service providers and private equity viewed as potential bidders.
inVentiv completes i3 acquisition
Acquisition hungry CRO inVentiv Health has completed the purchase of i3, positioning it for the next stage of its reorganisation plan.
INC buys Trident to expand in Phase I and Asia Pacific
INC Research is continuing its acquisition driven growth strategy by buying APAC-focused CRO Trident Clinical Research.
LabCorp to buy Clearstone to build Asia Pacific presence
LabCorp will buy Clearstone Central Labs in a deal that cements the firms’ existing clinical trial-focused collaboration.
Medpace joins list of CROs attracting private equity investment
New York-headquartered private equity investment group CCMP Capital will buy a majority stake in US CRO Medpace.
PRA International acquires key software developer; expands eClinical solutions
US contract research organisation (CRO) PRA International claims it intends to “reshape how the industry manages trials” after acquiring Indian eClinical software developer, Kinship Technologies, for an undisclosed amount.
inVentiv Health is to make PharmaNet its second CRO acquisition of the year as it aims to compete for strategic alliances.
Clinipace buys PFC to further global expansion plan
Clinipace has made PFC Pharma Focus its third acquisition in 18 months and is planning more takeovers to expand geographic reach.
Last week non-clinical CRO CIT bought Canadian counterpart LAB Research. Outsourcing-pharma.com spoke with CIT executive chairman Jean-Francois Le Bigot about the deal and the plan going forward.
INC Research to buy Kendle & aim at top 5 clinical CROs
INC Research is to acquire Kendle in a deal that would give it Phase II to IV clinical assets comparable to those at Covance.
Private equity CRO buying spree set to continue
Private equity firms have snapped up CROs over the past year and, with a number of vendors said to be up for sale, the trend is set to continue.
CIT completed Lab Research takeover
French contract research organisation (CRO) CIT has completed its acquisition of Canadian counterpart Lab Research.
Mitsui to buy MBS to bolster CMO and strengthen in China
Mitsui is to boost its intermediate, API and finished product CMO business and expand in China by buying MBS.
Strategic deals to drive market share gains for big CROs
The top seven CROs will have captured half the market by 2015 as big pharma, including Pfizer, enters into strategic relationships with major players, Jeffries & Company said.
Round up of M&A in pharma contract services
Outsourcing-Pharma presents a round up of contract services merger and acquisition activity, including deals at Evotec, Vyteris and Avantium Pharma.
CIT to buy Canada’s LAB Research
French preclinical contract research organisation (CRO) CIT has said it will buy Canadian counterpart LAB Research in a deal that would rescue the Quebec-based firm from the receivers.
INC plans acquisitions to add scale, reach and capabilities
INC Research plans to make at least one acquisition over the next year as it expands scale, capabilities and geographic reach.
Imperial acquires D. Anderson & Company; expands clinical trial services
Michigan, US-based clinical research organisation (CRO), Imperial, has completed the acquisition of clinical trial specialists, D. Anderson & Company for an undisclosed fee.
Quintiles may look at takeovers and strategic deals
The US contract research organization (CRO) Quintiles may look at acquisitions and more ‘strategic partnerships’ after securing a $2.43bn credit facility.
Kendle committed to early stage, says incoming CEO
The incoming Kendle CEO has stressed commitment to early stage and said dramatic changes in the short- to medium-term are unlikely.